Nachrichten zur Sutro Biopharma Aktie

Sutro Biopharma (STRO) delivered earnings and revenue surprises of -44.44% and 25.83%, respectively, for the quarter ended March 2025. Do…

Sutro Biopharma (STRO) delivered earnings and revenue surprises of -3.49% and 34.11%, respectively, for the quarter ended December 2024. Do…

…

Sutro Biopharma stock hits 52-week low at $2.02…

As every investor would know, not every swing hits the sweet spot. But you have a problem if you face…

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:…

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:…

Sutro Biopharma (STRO) gains 9% in a week after initiating a phase II study on its lead candidate, luvelta, to…

Short-term volatility is the hallmark of clinical-stage biopharma investing, and Sutro Biopharma (NASDAQ:STRO) is a fine example of that, recently…

Short-term volatility is the hallmark of clinical-stage biopharma investing, and Sutro Biopharma (NASDAQ:STRO) is a fine example of that, recently…

Sutro Biopharma (STRO) delivered earnings and revenue surprises of 151.22% and 834.90%, respectively, for the quarter ended December 2023. Do…

Sutro Biopharma, Inc. (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in…